Avantor, Inc. reports developments as a life science tools company supplying mission-critical products and services to life sciences and advanced technology customers through its VWR Distribution & Services and Bioscience & Medtech Products businesses. Recurring updates cover earnings, cash flow, leverage, guidance, segment performance and the company’s Revival transformation program, including VWR brand activity, manufacturing and supply-chain improvements and e-commerce upgrades.
Company news also covers portfolio and infrastructure actions such as Masterflex fluid handling systems, single-use assemblies, peristaltic pumps, J.T. Baker high-purity process chemicals, and expanded microbial and stability testing capabilities for regulated biopharma manufacturing. Governance and management updates include finance leadership changes and appointments tied to bioscience, medtech products and enterprise transformation.
Avantor (NYSE: AVTR) has announced the expansion of its Bridgewater, N.J. innovation center, nearly doubling laboratory and support space. This development aims to enhance R&D support for custom product and bioprocess development, including cell and gene therapy reagent manufacturing. The expansion aligns with the biopharma industry's focus on improving bioprocessing efficiency and complying with global regulatory standards. The site will also help minimize contamination risks in therapeutic product manufacturing.
Avantor, Inc. (NYSE: AVTR) announced its debut on the Fortune 500 list, ranking 484 based on revenue. Following its acquisition of VWR, Avantor has adapted its business model to meet demands in biopharma, healthcare, and applied technology. The company supports vaccine development amid COVID-19, serving over 225,000 customer locations globally. Key highlights include serving 10 of the top 10 medical device firms and having products specified in over 80% of the leading biologic drugs. Nearly half of its revenues come from biopharma, improving workflow in drug development.